Navigation Links
Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP

SCHAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia -- a potentially life-threatening irregular heart beat. Sagent's amiodarone HCl injection will be available immediately in 150 mg/3 mL single dose prefilled syringes. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $8 million. Amiodarone prefilled syringes are manufactured for Sagent by Gland Pharma.

"With our launch of the only multi-source, prefilled amiodarone syringe in the health care market, Sagent is making another essential product readily available to the emergency medicine community," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "In the emergency room, where seconds count, our product is ready-to-use -- and with enhanced labeling, easy to find on a crash cart. We are proud that our innovations to this important product, including a tamper-evident tip cap, yield safety enhancements that will potentially assist in saving patient's lives."

Amiodarone is the eighth product introduced from Sagent's pipeline of more than 200 products since the launch of the company's first product in December 2007.

About Amiodarone

Amiodarone HCl Injection, USP, is a class III antiarrhythmic indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Intravenous amiodarone can also be used to treat patients with ventricular fibrillation or ventricular tachycardia for whom oral amiodarone is indicated but who are not able to take oral medication. During or after treatment with intravenous amiodarone, patients may be transferred to oral amiodarone therapy. Intravenous amiodarone should be used for acute treatment until the patient's ventricular arrhythmias are stabilized.

The most common adverse effects may include dizziness or drowsiness; nausea, vomiting, stomach pain; insomnia; weakness, lack of coordination; or warmth, tingling or redness under the skin. Less common adverse effects include a new or worsening irregular heartbeat; wheezing, cough, chest pain, trouble breathing, coughing up blood; blurred vision, headache or pain behind the eyes; rapid weight gain; weight loss, thinning hair, increased sweating, irregular menstrual periods, swelling in the neck; numbness, burning, pain or tingling in the hands or feet; loss of appetite, dark urine, clay-colored stools, jaundice.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit

About Gland Pharma Ltd.

Established in 1978 as an exclusive facility for Small Volume Parenterals (SVPs), Gland Pharma has developed into a progressive and quality conscious organization serving the pharmaceutical needs of more than 25 countries across the globe. Gland Pharma has world-class and world-scale facilities for injectables set up in collaboration with the Vetter Group, Germany. Gland Pharma's research and development operation develops niche products from active pharmaceutical ingredient to finished dosages. Adenosine is one of many approved abbreviated new drug applications from the Gland Pharma's growing portfolio.

For more information about Gland Pharma, please visit

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
2. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
3. New Natural Product from Zurich Pharmaceuticals Downs Appetite
4. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
5. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
6. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
7. AUDIO from Medialink and Duramed Pharmaceuticals: Relief for Women Experiencing Surgical Menopause
8. Genesis Pharmaceuticals Announces SFDA Approval for Radix Isatidis Dispersible Tablets
9. Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer
10. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
11. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... at a University of Delaware Accounting and Management of Information Systems course. Based ... for mid-market businesses. Sommer will speak at before student in the Enterprise Resource ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... A ... 15th annual Regional Biotech Conference, organized by the Baruch S. Blumberg Institute. , The ... 100 of the area’s life science and biotechnology leaders for the conference, which focused ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced ... its hemorrhoid ointment to its website. , “Our goal is simple:” says Michael ... hemorrhoids. Adding the comparison chart and ingredient list allows our customers to quickly ...
(Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad , Chili ... maximize recovery through quality sleep. Tim DiFrancesco, training coach for the LA Lakers, ... sleep. ChiliPad precisely regulates the surface temperature of each side of the bed ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  PTS Diagnostics, the U.S.-based manufacturer ... analyzers, A1CNow ® systems, and PTS Detect™ ... of patents that will propel the company into the ... Europe . The technology is a ... those on smartphones and tablets, and uses test strip ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), ... present live at on December 3, 2015. ... TIME: 3:15p.m. ET LINK: ... LINK: --> ... event where investors are invited to ask the company questions ...
(Date:11/30/2015)... LAKE CITY , Nov. 30, 2015 Booth ... (NYSE: VAR ) will exhibit a broader array of ... of the Radiological Society of North America ... Varian exhibit at the meeting will feature X-ray components "At ... CT tube, a line of products from Varian,s Claymount brand, ...
Breaking Medicine Technology: